We have signed an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate for #Behçets Disease. The topical muco-adherent formulation of Pentoxifylline to treat oral ulcers has FDA Fast Track and Orphan Designation, positive Phase 2 data, and is positioned for potential 505(b)(2) regulatory pathway in the U.S. that can result in a much less expensive and much faster route to approval and commercialisation. There is a clear unmet medical need for an effective treatment for this rare disease, which currently has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impacts essential functions like eating, drinking and speaking. Read full announcement here: https://lnkd.in/ePAg63sW #POLB #Behçets #BehçetsDisease #raredisease #orphan
Poolbeg Pharma plc
Biotechnology Research
Committed to the development and commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
Queen Mary BioEnterprises Innovation Centre, 42 New Road
London, E1 2AX, GB
-
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at European Green Transition, Co-Founder of…
Updates
-
Join us in promoting Diabetes Week 2024, as we unite to raise awareness on diabetes, a health condition affecting millions worldwide. This week is dedicated to educating the public, supporting those living with diabetes and advocating for better healthcare and research. At Poolbeg Pharma plc, we are developing an oral GLP-1R agonist for diabetes and obesity. Global supply of GLP-1R agonists is currently, and predicted to remain, constrained by manufacturing capacity. Any technology which can improve bioavailability in patients has the potential to significantly reduce global shortages and improve access to patients. We hope our contributions will make a difference! 💊🌍 #DiabetesWeek2024 #DiabetesAwareness #Healthcare #Diabetes
-
That's a wrap! We attended this weeks' Biotechnology Innovation Organization International Convention in San Diego ☀️📷 The team was delighted to have connected🤝 with so many industry colleagues and potential partners🔬 to discuss our exciting portfolio of high value programmes. #POLB #POLBF
-
Check out our latest Poolbeg Pharma plc Factsheet! 🔬 Commitment to the development & commercialisation of innovative medicines 🤝 Addressing critical unmet medical needs 🌱 Growing emphasis on rare & orphan diseases Scroll down our investors page and download it here ⬇️ https://lnkd.in/dpyXXap #POLB
-
Regulatory authorities offer incentives to companies developing 🧬orphan drugs In the US, it grants seven years of market exclusivity to the sponsor upon marketing authorisation as well as some other benefits 💡 This exclusivity encourages pharmaceutical companies to invest in researching and developing treatments for rare diseases, where the potential patient population might be small but the impact on individuals' lives is immense🌍 #POLB #OrphanDrugs #Rarediseases #DrugDevelopment
-
We entered an exclusive option agreement to acquire an orphan drug candidate. Here is an overview of the Orphan Drug Candidate tPTX for Behçet's Disease from Timothy Cote, the CEO of Silk Road Therapeutics at our recent Investor Meet Company presentation. ☑️ Demonstrating superiority over standard of care 🎯 Addressing unmet need 🏃 Positioned for a potential 505(b)(2) approval pathway in the U.S Watch the full Investor Meet Company presentation: https://lnkd.in/edmN3aEp #POLB #POLBF #BehçetsDisease
-
Conference Reminder 🚨 we are attending the upcoming Biotechnology Innovation Organization International Convention on 3-6 June in San Diego, California. Meet with the team by connecting via the BIO One-on-One Partnering System: https://lnkd.in/eEDtKaAK #POLB #POLBF #BIOConvention #SanDiego #BIO24
-
Our CEO Jeremy Skillington, PhD featured on the latest Optimum Strategic Communications podcast episode dedicated to 🤖#ArtificialIntelligence in drug development, alongside the CEO & Co-founder of SimBioSys, Inc. 🔬AI in the drug development & pharma space 🦾AI overcoming industry challenges 🔍 Ethical considerations 🚀 Poolbeg Pharma plc's AI Programmes Make sure to tune in🎧 https://lnkd.in/dZWYypZM #AI #POLB #DrugDevelopment
-
We will be presenting with PI World at 2pm on Wednesday 20 June. Tune in 👂 to hear the latest updates from Poolbeg Pharma plc, register to attend💻 here: https://lnkd.in/gAEWQUzJ #POLBF #CompanyPresentation
-
Our CEO Jeremy Skillington, PhD caught up with Sarah Lowther to recap on our exciting recent news: ✅ Exclusive Option to Acquire Orphan Drug Candidate 🤝 Appointment of Joint Broker ☑️ Significant POLB 001 Patent Granted in the US Tune in: https://lnkd.in/etwznd7C #POLB #POLBF
Immense promise for cashed up Poolbeg Pharma
https://www.youtube.com/